New BEACON

In this video, Dr Martina Eriksen, medical oncologist at the Rigshospitalet in Copenhagen (Denmark) shares the results of an interim analysis of the New-BEACON study. This trial evaluates cetuximab given every second week together with daily encorafenib in the second line treatment of patients with BRAF-mutant metastatic colorectal cancer (mCRC). Interim data of this trial showed a 2-month progression free survival (PFS) rate of 89%, which is comparable to the results obtained in the BEACON trial evaluating a weekly administration of cetuximab. As such, these results suggest that cetuximab every second week may be suitable alternative to weekly cetuximab in this setting.